Drug
Tak 831 T2
Tak 831 T2: highest development phase Phase 1, developed by Neurocrine Biosciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| TAK-831 T2 NCT03706469 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Tak 831 T2 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.